TY - JOUR
T1 - Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome
T2 - A 3-year population-based retrospective cohort study in taiwan
AU - Lin, Chen Fang
AU - Gau, Churn Shiouh
AU - Wu, Fe Lin Lin
AU - Hsiao, Fei Yuan
AU - Bai, Chyi Huey
AU - Shen, Li Jiuan
N1 - Funding Information:
This work was supported by a grant ( DOH99-FDA-41005 and DOH99-TD-B-111-001 ) from the Bureau of Food and Drug Administration, Department of Health , Taiwan. All of the authors contributed to the conception and design, the acquisition of data, and the analysis and interpretation of data. The authors have indicated that they have no other conflicts of interest regarding the content of this article. There was no industry involvement in the funding, design, analysis, presentation, or publication of this study.
PY - 2011/9
Y1 - 2011/9
N2 - Background: Conflicting results using the combination of ezetimibe and statins to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS) have been reported. Objective: The aim of this work was to assess the effectiveness of ezetimibe coadministered with statins in reducing cardiovascular events in patients with ACS. Methods: A retrospective cohort study of patients discharged after hospitalization with ACS was conducted from January 1, 2006, to December 31, 2007, and included those who were prescribed statins alone (n = 37,753) and those who received ezetimibe plus statins (n = 1001) within 365 days after the hospitalization, based on patient data obtained from the National Health Insurance Research Database (NHIRD) in Taiwan. The propensity score method was used to identify a 1:1 matched cohort (n = 2002). Risk of rehospitalization for ACS was analyzed by a multivariable Cox proportional hazards regression model. Results: The crude event rate of rehospitalization due to ACS in the original cohort was 13.4 per 100 person-years (268 events) in the combination group and 22.6 per 100 person-years (12,724 events) in the statins-alone group (adjusted hazard ratio [HR] 0.69; 95% CI, 0.62-0.78). The crude event rates of rehospitalization due to ACS in the matched cohort were 13.4 and 20.0 per 100 person-years in the combination group and statins-alone group, respectively (HR 0.62; 95% CI, 0.53-0.73). Compared with statins alone, the adjusted HRs for rehospitalization for percutaneous transluminal coronary angioplasty without stent, with stent, and revascularization for the combination group in the matched cohort were 0.61 (0.50-0.75), 0.62 (0.48-0.81), and 0.62 (0.51-0.76), respectively. Conclusions: Based on the data of Taiwan's NHIRD, our findings suggest that patients with ACS on ezetimibe combined with statins had a significantly lower risk of rehospitalization due to ACS, percutaneous transluminal coronary angioplasty, and revascularization than those on statins alone. The generalization of the results is limited because of using claims data of a specific population as the data source.
AB - Background: Conflicting results using the combination of ezetimibe and statins to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS) have been reported. Objective: The aim of this work was to assess the effectiveness of ezetimibe coadministered with statins in reducing cardiovascular events in patients with ACS. Methods: A retrospective cohort study of patients discharged after hospitalization with ACS was conducted from January 1, 2006, to December 31, 2007, and included those who were prescribed statins alone (n = 37,753) and those who received ezetimibe plus statins (n = 1001) within 365 days after the hospitalization, based on patient data obtained from the National Health Insurance Research Database (NHIRD) in Taiwan. The propensity score method was used to identify a 1:1 matched cohort (n = 2002). Risk of rehospitalization for ACS was analyzed by a multivariable Cox proportional hazards regression model. Results: The crude event rate of rehospitalization due to ACS in the original cohort was 13.4 per 100 person-years (268 events) in the combination group and 22.6 per 100 person-years (12,724 events) in the statins-alone group (adjusted hazard ratio [HR] 0.69; 95% CI, 0.62-0.78). The crude event rates of rehospitalization due to ACS in the matched cohort were 13.4 and 20.0 per 100 person-years in the combination group and statins-alone group, respectively (HR 0.62; 95% CI, 0.53-0.73). Compared with statins alone, the adjusted HRs for rehospitalization for percutaneous transluminal coronary angioplasty without stent, with stent, and revascularization for the combination group in the matched cohort were 0.61 (0.50-0.75), 0.62 (0.48-0.81), and 0.62 (0.51-0.76), respectively. Conclusions: Based on the data of Taiwan's NHIRD, our findings suggest that patients with ACS on ezetimibe combined with statins had a significantly lower risk of rehospitalization due to ACS, percutaneous transluminal coronary angioplasty, and revascularization than those on statins alone. The generalization of the results is limited because of using claims data of a specific population as the data source.
KW - Acute coronary syndrome
KW - Coadministered
KW - Ezetimibe
KW - Prevention
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=80053043988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053043988&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2011.08.002
DO - 10.1016/j.clinthera.2011.08.002
M3 - Article
C2 - 21872930
AN - SCOPUS:80053043988
SN - 0149-2918
VL - 33
SP - 1120
EP - 1131
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 9
ER -